

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to Commissioner for Patents, Washington, DC 20231, on the date shown below
Dated 2/4/03 Signature Ann P Lucey
(Anna P Lucey)

162
Docket No.: ASON-P01-47

RECEIVED
TECH CENTER 1600
FEB 17 2003
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Faull et al.

Application No.: 09/889515

Group Art Unit: 1626

Filed: October 10, 2001

Examiner: Wright, Sonya N.

For: ANTI-INFLAMMATORY INDOLE
DERIVATIVES

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
Washington, DC 20231

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned.

A copy of each reference on PTO/SB/08 is attached.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents should one or more of the documents be used against the claims of the present application.

The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. ASZD-P01-471.

Dated:

Respectfully submitted,

By 
David P. Halstead, Ph.D.

Registration No.: 44,735
ROPES & GRAY
One International Place
Boston, Massachusetts 02110-2624
(617) 951-7000
(617) 951-7050 (Fax)
Attorneys for Applicant

Form PTO SB 08
**INFORMATION DISCLOSURE CITATION
 IN AN APPLICATION**
(Use several sheets if necessary)

FEB 07 2003

Docket Number (Optional) ASZD-P01-471	Application Number 09 889,515
Applicant Faull et al.	
Filing Date October 10, 2001	Group Art Unit 1626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE

RECEIVED
 FEB 07 2003
 TECH CENTER 1800 2900

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation
						YES NO
AA	DE 298 913 a5	3/1992	Germany			X
AB	EP 0 189 690	8/6/86	EPO			
AC	EP 0 419 049 A1	3/27/91	EPO			
AD	EP 0 480 659 A2	4/15/92	EPO			
AE	EP 0 535 923 A1	4/7/93	EPO			
AF	EP 0 535 924 A1	4/7/93	EPO			
AG	EP 0 535 925 A1	4/7/93	EPO			
AH	EP 0 535 926 A1	4/7/93	EPO			
AI	EP 0 639 573 A1	2/22/95	EPO			Abstract
AJ	EP 0 822 185	2.4.98	EPO			
AK	EP 0 275 667	7/27/98	EPO			
AL	FR 2 565 981	12/20/85	France			Abstract
AM	JP 63284177	11/21/88	Japan			Abstract
AN	JP 4273857	9/30/92	Japan			Abstract
AO	WO 86 00896	2 13 86	WIPO			
AP	WO 92 04343	3 19 92	WIPO			
AQ	WO 93 16069	8 19 93	WIPO			
AR	WO 93 20078	10 14 93	WIPO			
AS	WO 94 14434	7 7 94	WIPO			

For PTO SB 08
INFORMATION DISCLOSURE CITATION
IN AN APPLICATION
(Use several sheets if necessary)

FEB 8 2003

Docket Number (Optional)
ASZD-P01-471

Application Number
09 889,515

Applicant
Faull et al.

Filing Date
October 10, 2001

Group Art Unit
1626

AW	WO 97/13615	4/10/97	WIPO			
AX	WO 97/30704	8/28/97	WIPO			
AY	WO 97/35572	10/2/97	WIPO			
AZ	WO 98/06703	2/19/98	WIPO			

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages Etc.)

BA	Berman, J.W. et al. Localization of Monocyte Chemoattractant Peptide-1 Expression in the Central Nervous System in Experimental Autoimmune Encephalomyelitis and Trauma in the Rat. <i>J. Immunol.</i> 156, 3017-3023 (1996).
BB	Bobosik, V. & Krutosikova, A. Synthesis of N-Phenylsulfonyl Protected Furo[3,2-b]Pyrroles. <i>Collect. Czech. Chem. Commun.</i> 59, 499-502 (1994).
BC	Dandarova, M. ¹³ C NMR Spectra of Some Substituted Furo[3,2-b]pyrroles. <i>Magnetic Resonance Chem.</i> 28, 830-831 (1990).
BD	Deleuran, M. et al. Localization of monocyte chemotactic and activating factor (MCAF/MCP-1) in psoriasis. <i>J. Dermatological Sci.</i> 13, 228-236 (1996).
BE	Grimm, M.C. et al. Enhanced expression and production of monocyte chemoattractant protein-1 in inflammatory bowel disease mucosa. <i>J. Leukocyte Biol.</i> 59, 804-812 (June 1996).
BF	Harrison, C.-A. et al. Cyclopenta [b] indoles. Part 2. Model studies towards the tremorgenic mycotoxins. <i>J. Chem. Soc. Perkin Trans.</i> 1131-1136 (1995).
BG	Hartman, G.D. & Halezenko, W. The Synthesis of 5-Alkylaminomethylthieno[2,3-b]pyrrole-5-sulfonamides. <i>Heterocycles</i> 29, 1943-1949 (1989).
BH	Jones, M.L. et al. Potential Role of Monocyte Chemoattractant Protein 1 (MCP-1) in Monocyte/Macrophage-Dependent IgA Immune Complex Alveolitis in the Rat. <i>J. Immunol.</i> 149, 2147-2154 (15 Sept. 1992).
BI	Kataoka, K. et al. Homopiperazines as cell migration inhibitors. <i>Chemical Abstracts</i> , Columbus Ohio, US 123, 667 (2 October 1995).
BJ	Koch, A.E. et al. Enhanced Production of Monocyte Chemoattractant Protein-1 Rheumatoid Arthritis. <i>J. Clin. Invest.</i> 90, 772-779 (Sept. 1992).
BK	Korobchenko, I.V. et al. Synthesis and antiviral activity of pyrrolecarboxylic acids and their derivatives. <i>Chemical Abstracts</i> Columbus, Ohio, Access Number: 119-62465 (1999)
BL	Krutosikova, A. & Dandarova, M. Substituted Vinyl Azides in Synthesis of Furo[3,2-b:4,5-b]-Dipyrrroles and Pyrrolo[2',3':4,5]Furo[3,2-c]Pyridines. <i>Heterocycles</i> 37, 1695-1700 (1994).
BM	Krutosikova, A. & Dandarova, M. Reactions of Methyl 2-Formylfuro[3,2-b]pyrrole-5-carboxylates. <i>Chem. Papers</i> 50, 72-76 (1996)

For: PTO SB 08
**INFORMATION DISCLOSURE CITATION
 IN AN APPLICATION**
(Use several sheets if necessary)

Docket Number (Optional)	ASZD-P01-471	Application Number	09 889.515
Applicant	Faull et al.	FEB 11 2003	
Filing Date	October 10, 2001	Group Art Unit	1626

BO	Krutosikova, A. et al. Condensed O-, N-Heterocycles by the Transformation of Azidoacrylates. <i>Chemical Monthly</i> 123, 807-815 (1992).
BP	Krutosikova, A. et al. Derivatives of Euro[3.2-b]Pyrrole. <i>Collect. Czech. Chem. Commun.</i> 59, 473-481 (1994).
BQ	Krutosikova, A. et al. Substituted Vinyl Azides in the Synthesis of Condensed Nitrogen Heterocycles. <i>Chem. Papers</i> 48, 268-273 (1994).
BR	Krutosikova, A. et al. Synthesis and Reactions of Euro[3.2-b]Pyrrole Type Aldehydes. <i>Collect. Czech. Chem. Commun.</i> 58, 2139-2149 (1993).
BS	Krutosikova, A. et al. Synthesis and Reactions of Euro[2.3-b]pyrroles. <i>Molecules</i> 2, 69-79 (1997).
BT	Murakami, Y. et al. Direct Regioselective Vinylation of Indoles Using Palladium (II) Chloride. <i>Heterocycles</i> 22, 1493-1496 (1984).
BU	Rosenmund, P. et al. Decarboxylations of Some 1-Alkyl-2-carboxy-3-indolacetic Acids and Synthesis of a 5-Thiocyanato-2,3-dihydroindole. <i>Chem. Ber.</i> 108, 3538-3542 (1975). - Abstract only.
BV	Troschutz, R. & Hoffmann, A. Synthesis of Substituted 3-Amino-4-cyano-1-oxo-1,2,5,10-tetrahy-droazepino[3,4-b]indoles. <i>J. Heterocyclic Chem.</i> 34, 1431 (1997).
BW	Yokoyama, Y. et al. Palladium-Catalyzed Cross-Coupling Reaction: Direct Allylation of Aryl Bromides with Allyl Acetate. <i>Tetrahedron Letters</i> 26, 6457-6460 (1985).
BX	Yokoyama, Y. et al. New Synthetic Method for Dehydrotryptophan Derivatives. Synthesis Studies on Indoles and Related Compounds. XXIV. <i>Chem. Pharm. Bull.</i> 42, 832-838 (1994).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.